Archive \ Volume.14 2023 Issue 2

Review of Duloxetine Use in the Management of Stress Urinary Incontinence and Students’ Survey

Oluwatosin Dairo, Imani Akram, Christopher Bratcher, Bisrat Hailemeskel

The goal of this study is to assess the knowledge and opinion of students regarding the off-label use of duloxetine in the treatment of SUI. The Survey questions were provided during the Drug Information Course at Howard University (HU) College of Pharmacy in a class where first-year pharmacy students learn how to conduct a literature search and a survey. A total of 39 students responded to the survey. There were more females (n=23; 56.1%) with an age range between 18 – 24 years. About two-thirds (n=29; 70.7%) had a four-year degree before starting the pharmacy program. Overall, participants scored less than the passing 70% mark on the knowledge questions, which may call for educators to make a special effort to incorporate off-label and approved indications of medication teaching therapeutic-related courses. For example, more than sixty percent of respondents (n=25; 61%) incorrectly stated that duloxetine is a narrow therapeutic drug. The majority (n=; 34; 82.9%) of the participants responded wrongly that urinary incontinence is more common in women during their childbearing age. The opinion survey showed that most participants (n=25; 61%) did not believe there were many FDA-approved effective drugs for treating UI. Over sixty percent of participants (n=25; 61%) considered UI a severe illness and did not agree to use a non-approved drug such as duloxetine, although several published clinical studies support its effective use. Participants were split in their opinion regarding the non-approved use of medications. Study results suggest that students may need encouragement to explore medications with non-FDA approvals.

Downloads: 22
Views: 26

How to cite:
Dairo O, Akram I, Bratcher C, Hailemeskel B. Review of Duloxetine Use in the Management of Stress Urinary Incontinence and Students’ Survey. Arch Pharm Pract. 2023;14(2):54-8.
Dairo, O., Akram, I., Bratcher, C., & Hailemeskel, B. (2023). Review of Duloxetine Use in the Management of Stress Urinary Incontinence and Students’ Survey. Archives of Pharmacy Practice, 14(2), 54-58.

Download Citation

1.        Women’s bladder and bowel health conditions. National Association For Continence. 2022. Available from: (Accessed: January 18, 2023).

2.        Lugo T, Riggs J. Stress Incontinence. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022. Available from:

3.        Sweeney DD, Chancellor MB. Treatment of stress urinary incontinence with duloxetine hydrochloride. Rev Urol. 2005;7(2):81-6.

4.        Jost WH, Marsalek P. Duloxetine in the treatment of stress urinary incontinence. Ther Clin Risk Manag. 2005;1(4):259-64.

5.        Norton PA, Zinner NR, Yalcin I, Bump RC. Duloxetine Urinary Incontinence Study Group. Duloxetine versus placebo in the treatment of stress urinary incontinence. Am J Obstet Gynecol. 2002;187(1):40-8. doi:10.1067/mob.2002.124840

6.        Dmochowski RR, Miklos JR, Norton PA, Zinner NR, Yalcin I, Bump RC, et al. Duloxetine versus placebo for the treatment of North American women with stress urinary incontinence. J Urol. 2003;170(4 Pt 1):1259-63. doi:10.1097/ 

7.        Ghoniem GM, Van Leeuwen JS, Elser DM, Freeman RM, Zhao YD, Yalcin I, et al. A randomized controlled trial of duloxetine alone, pelvic floor muscle training alone, combined treatment and no active treatment in women with stress urinary incontinence. J Urol. 2005;173(5):1647-53.

8.        Maund E, Guski LS, Gøtzsche PC. Considering benefits and harms of duloxetine for treatment of stress urinary incontinence: a meta-analysis of clinical study reports. CMAJ. 2017;189(5):E194-E203. doi:10.1503/cmaj.151104

9.        Wittich CM, Burkle CM, Lanier WL. Ten common questions (and their answers) about off-label drug use. Mayo Clin Proc. 2012;87(10):982-90. doi:10.1016/j.mayocp.2012.04.017

10.      Radley DC, Finkelstein SN, Stafford RS. Off-label prescribing among office-based physicians. Arch Intern Med. 2006;166(9):1021-6. doi:10.1001/archinte.166.9.1021

11.      Chen H, Reeves JH, Fincham JE, Kennedy WK, Dorfman JH, Martin BC. Off-label use of antidepressant, anticonvulsant, and antipsychotic medications among Georgia Medicaid Medicaid enrollees in 2001. J Clin Psychiatry. 2006;67(6):972-82.

12.      Kannan S, Bahl A, Khosla PP. Knowledge and perception of off-label drug use amongst prescribing physicians in a tertiary care hospital. Int J Risk Saf Med. 2015;27(4):219-23. doi:10.3233/JRS-150664

13.      Mukattash TL, Alzoubi KH, Abuirjie AM, Jarab AS, Farha RK, Nusair MB, et al. Perceptions and attitudes towards off-label dispensing for pediatric patients, a study of hospital basedhospital-based pharmacists in Jordan. Saudi Pharm J. 2018;26(1):20-4. doi:10.1016/j.jsps.2017.11.004

14.      AHRQ. Off-Label Drugs: What You Need to Know. Available from:,are%20for%20off%2Dlabel%20use. 2/8/2023

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.